ABT-199 is an anti-apoptotic protein Bcl-2 inhibitor that mimics BH3-only proteins, the native ligands of Bcl-2 and programmed cell death activators, repressing Bcl-2 activity and restoring apoptotic processes in tumor cells.
March 19, 2019 The FDA has placed a partial clinical hold on all clinical trials examining venetoclax (Venclexta) in multiple myeloma, halting enrollment of new patients on the studies, according to AbbVie, which jointly develops the BCL-2 inhibitor with Genentech (Roche). Read more...
View all active clinical trials around the US.
The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.
The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.